Effects of intracerebroventricular infusion of leptin in obese Zucker rats.
The obese Zucker rat (OZR) exhibits a missense mutation in the cDNA for the leptin receptor, producing a single amino acid substitution in the extracellular domain of the receptor. A mutation in the leptin receptor gene of the db/db mouse prevents the synthesis of the long splice variant of the receptor. The possibility that the OZR, like the db/db mouse, is refractory to the actions of murine leptin was tested by infusing the protein intracerebroventricularly via a minipump for 7 days. Lean Zucker rats (LZR) infused with leptin acted as positive controls, and other groups of OZR and LZR were infused with vehicle. In LZR, leptin reduced bodyweight and food intake and increased brown adipose tissue (BAT) temperature. Plasma corticosterone increased (61%) in these rats, and plasma triglycerides fell (78%). Leptin treatment improved tolerance to an oral glucose load (16% reduction in the area under the blood glucose curve) while lowering plasma insulin. In OZR, the actions of leptin were blunted. Food intake was slightly, but not significantly, reduced. Although there was a reduction in the rate of increase in body mass, the effect of leptin was about half that seen in LZR. BAT temperature and glucose tolerance were unchanged. In contrast to the elevated plasma corticosterone seen in LZR, leptin reduced the level of this hormone (27%) in OZR. In OZR and LZR treated with leptin, the plasma leptin levels were increased 24-fold and 47-fold, respectively. The results suggest that leptin retains some efficacy in OZR, although these rats are less responsive than LZR.
al-Barazanji
K A
KA
SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
Buckingham
R E
RE
Arch
J R
JR
Haynes
A
A
Mossakowska
D E
DE
McBay
D L
DL
Holmes
S D
SD
McHale
M T
MT
Wang
X M
XM
Gloger
I S
IS
D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000503:physiopathology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001831:Body Temperature; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D003345:Corticosterone / Q000097:blood; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism; D015918:Infusion Pumps, Implantable; D007328:Insulin / Q000097:blood; D020738:Leptin; D008297:Male; D051379:Mice; D009765:Obesity / Q000503:physiopathology*; D011506:Proteins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker; D011994:Recombinant Proteins / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D011506:Proteins; D011994:Recombinant Proteins; D014280:Triglycerides; D003345:Corticosterone